PF 5251749

Drug Profile

PF 5251749

Alternative Names: PF-05251749; PF5251749

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antidementias
  • Mechanism of Action Casein kinase Idelta modulators; Casein kinase Iepsilon modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 10 Feb 2017 Pfizer completes a phase I trial in Alzheimer's disease (In volunteers, In adults, In the elderly) in USA (NCT02691702)
  • 01 Mar 2016 Pfizer initiates a phase I trial in Alzheimer's disease (In volunteers, In adults, In the elderly) in USA (NCT02691702)
  • 29 Feb 2016 Pfizer plans a phase I trial in Alzheimer's disease (In volunteers, In adults, In the elderly) in USA (NCT02691702)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top